ATRIUM HEALTH, WAKE FOREST BAPTIST HEALTH, WAKE FOREST SCHOOL OF MEDICINE
AND RENALYTIX PARTNER TO ADVANCE KIDNEY HEALTH
Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management
NEW YORK, CHARLOTTE AND WINSTON-SALEM, N.C., May, 19 2021
-- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), Atrium Health,
Wake Forest Baptist Health
and
Wake Forest School of Medicine
announced a partnership to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations.
The KidneyIntelX bioprognostic platform for early-stage diabetic kidney disease risk assessment will be available through Atrium Health's electronic health record (EHR) system, providing access to primary care physicians, endocrinologists, nephrologists and care teams throughout 37 hospitals and more than 1,350 care locations across the Carolinas and Georgia. Charlotte, North Carolina-based Atrium Health serves more than 7 million people in the region, providing care under the Wake Forest Baptist Health name in the Winston-Salem, N.C. region and Atrium Health Navicent in Georgia.